-
Archives
- December 2017
- June 2017
- May 2017
- February 2017
- November 2016
- October 2016
- September 2016
- July 2016
- April 2016
- March 2016
- December 2015
- August 2015
- April 2015
- February 2015
- January 2015
- December 2014
- November 2014
- September 2014
- August 2014
- July 2014
- May 2014
- January 2014
- December 2013
- November 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
-
Meta
Search Results for: testosterone replacement therapy
Caveat Emptor: Direct-to-Consumer (DTC) Ads for Testosterone Replacement Therapy Soar
“Ted,” a 50-year-old bicycle racer from Philadelphia, saw his primary care doctor for the last time several months ago– when he was advised to start testosterone replacement therapy. “Your labs are excellent,” said Ted’s doctor. “I’d like to frame them.” … Continue reading
Testosterone Replacement Trials Proceed Slowly
(part 2 of 2 posts) Alerting men to screening and treatment for low testosterone may get them in to their doctors faster, but they may be astounded to learn that the science in the field is wanting. The National Institute … Continue reading
Posted in direct-to-consumer marketing, drug safety, elderly, men's health
Tagged hormone replacement, Institute of Medicine, National Institute of Aging, testosterone replacement therapy
Comments Off on Testosterone Replacement Trials Proceed Slowly
AARP: Stakeholder for Waste and Moneyed Interests?
AARP, you lost whatever presumed credibility you thought you had with one article in the current issue of your magazine. I am talking about the hard copy of “All the President’s Scans: Our Commander in Chief Regularly Gets An Extensive … Continue reading
Posted in AARP
Tagged Executive physicals, misuse, overdiagnosis, overtreatment, overuse, premiums, stakeholders, value, value-based healthcare, waste
Comments Off on AARP: Stakeholder for Waste and Moneyed Interests?